Redhill Biopharma Ltd. - American Depositary Shares (RDHL)

Competitors to Redhill Biopharma Ltd. - American Depositary Shares (RDHL)

Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals develops a variety of drugs for gastrointestinal and other diseases, placing them in direct competition with Redhill. Arena's existing product portfolio and pipeline aim to tackle serious issues in immunology, which gives them a robust platform. Their significant financial backing and operational scale position them ahead of Redhill in terms of research capabilities and clinical trial execution.

Aurinia Pharmaceuticals Inc. 

Aurinia Pharmaceuticals specializes in developing treatments for autoimmune diseases, which creates direct competition with Redhill Biopharma's gastrointestinal focus. The two companies may target overlapping patient populations in the immunology space. Aurinia's recent success with their approved product, Lupkynis, showcases their effective commercialization strategy, providing them with a market advantage due to their demonstrated clinical efficacy and revenue generation.

Catalyst Pharmaceuticals, Inc. 

Catalyst Pharmaceuticals focuses on developing and commercializing innovative therapies for neurological diseases, similar to Redhill Biopharma. Both companies aim to address unmet medical needs but compare closely in the specialty pharmaceutical space. However, Catalyst has successfully brought several products to market and has a more established commercial presence, giving them an edge in terms of market access and sales capabilities.

Impel NeuroPharma, Inc.

Impel NeuroPharma is focused on developing unique drug delivery systems for neurological disorders, which may indirectly compete with some of Redhill's gastrointestinal therapies that have central nervous system implications. However, Impel's cutting-edge technology and innovation in drug delivery give them an advantage in enhancing therapeutic outcomes and patient adherence, making their products more appealing in a competitive landscape.

Strongbridge Biopharma plc

Strongbridge Biopharma is engaged in developing and commercializing therapies for rare diseases and endocrine disorders. This aligns closely with Redhill's focus on gastrointestinal diseases and rare conditions. While both companies are working to innovate within niche therapeutic areas, Strongbridge has a stronger pipeline of approved products and ongoing clinical trials, thus providing them with a competitive advantage in product availability and market penetration.